 |
|
|
|
|
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Longwood Fund
| | | | | Phone: | (617) 351-2590 | | Year Established: | 2010 | | Main Contact: | Rich Aldrich, Partner & Founder | | | | Other Contacts: | Christoph Westphal, M.D., Ph.D., Partner & Founder
Michelle Dipp, M.D., Ph.D., Partner & Founder
| | | | Company Description | | Longwood’s mission is to identify technologies and to found companies that will advance new therapeutics that can not only make a difference in the lives of patients worldwide, but also create significant value for investors. This is achieved by leveraging the management team’s history of successful biotechnology company formation and operational leadership. Longwood’s portfolio includes Alnara Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2010 for $180 million cash upfront and a $200 million earn-out, and Verastem, Inc., a biotechnology company focused on discovering and developing novel drugs that selectively target cancer stem cells. Members of the Longwood team have founded and built several successful biotechnology companies including Momenta Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Sirtris Pharmaceuticals, Inc., and Alnara Pharmaceuticals, Inc. | |
|
|
|
|
|
|
|
